Psychiatric Assessments

DIAGNOSTIC_TEST2 trials

Sponsors

Biomind Labs Inc.

Conditions

Anxiety StateDepression Anxiety DisorderHealthy VolunteersMild Cognitive Impairment

Phase 1

Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI

CompletedNCT06812221

Biomind Labs Inc.Anxiety State, Depression Anxiety Disorder, Mild Cognitive Impairment

Start: 2024-12-15End: 2025-03-15Updated: 2025-04-09

Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety

CompletedNCT06816667

Biomind Labs Inc.Healthy Volunteers

Start: 2024-10-21End: 2025-03-01Updated: 2025-03-05

Related Papers

Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled study.

2025-07-151 citations